NMIBC Treatment Landscape
Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Janet Kukreja, MD, MPH, FACS
CME Available: auau.auanet.org/node/44076
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
AstraZeneca
Johnson & Johnson
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Select and implement immunotherapy regimens for patients with NMIBC in accordance with current AUA Guideline recommendations, tailoring treatment choices to tumor characteristics and individual patient needs.
2. Incorporate FDA-approved gene therapy options into NMIBC management by aligning therapeutic approaches with patient-specific factors, disease risk profile, and evolving clinical evidence.
3. Develop and integrate practical strategies to anticipate, monitor, and manage treatment-related side effects and immune-related adverse events in NMIBC, ensuring patient safety and treatment continuity.
All content for AUAUniversity is the property of American Urological Association and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
NMIBC Treatment Landscape
Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Janet Kukreja, MD, MPH, FACS
CME Available: auau.auanet.org/node/44076
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
AstraZeneca
Johnson & Johnson
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Select and implement immunotherapy regimens for patients with NMIBC in accordance with current AUA Guideline recommendations, tailoring treatment choices to tumor characteristics and individual patient needs.
2. Incorporate FDA-approved gene therapy options into NMIBC management by aligning therapeutic approaches with patient-specific factors, disease risk profile, and evolving clinical evidence.
3. Develop and integrate practical strategies to anticipate, monitor, and manage treatment-related side effects and immune-related adverse events in NMIBC, ensuring patient safety and treatment continuity.
AUA2025: Chemotherapy and Immunotherapy for Urologists and Advanced Practice Providers (APPs)
AUAUniversity
1 hour 59 minutes 34 seconds
5 months ago
AUA2025: Chemotherapy and Immunotherapy for Urologists and Advanced Practice Providers (APPs)
AUA2025: Chemotherapy and Immunotherapy for Urologists and Advanced Practice Providers (APPs)
CME Available: https://auau.auanet.org/node/43009
At the conclusion of this activity, participants will be able to:
1. Identify the guidelines for first-line and beyond treatment of patients with hormone-sensitive advanced and metastatic prostate cancer, including medications, their mechanism, side effects and efficacy.
2. Summarize the recommendations for first-line and beyond treatment of castrate-resistant metastatic and nonmetastatic prostate cancer, including medications, their mechanism, side effects and efficacy.
3. Diagram the treatment options for high-risk non-muscle invasive bladder cancer.
4. Distinguish the guideline-defined therapeutic options for locally advanced and metastatic bladder cancer.
5. Discuss treatment options for locally advanced and metastatic kidney cancer, including medications, their mechanism, side effects and efficacy.
ACKNOWLEDGEMENTS:
This educational activity is supported by independent educational grants from:
Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
AUAUniversity
NMIBC Treatment Landscape
Host: Mark L. Gonzalgo, MD, PhD, MBA
Guest: Janet Kukreja, MD, MPH, FACS
CME Available: auau.auanet.org/node/44076
ACKNOWLEDGEMENTS:
Support provided by independent educational grants from:
AstraZeneca
Johnson & Johnson
LEARNING OBJECTIVES:
At the conclusion of this activity, participants will be able to:
1. Select and implement immunotherapy regimens for patients with NMIBC in accordance with current AUA Guideline recommendations, tailoring treatment choices to tumor characteristics and individual patient needs.
2. Incorporate FDA-approved gene therapy options into NMIBC management by aligning therapeutic approaches with patient-specific factors, disease risk profile, and evolving clinical evidence.
3. Develop and integrate practical strategies to anticipate, monitor, and manage treatment-related side effects and immune-related adverse events in NMIBC, ensuring patient safety and treatment continuity.
